Escitalopram and Depression in Elderly Alzheimer's Patients

Verified by: University of British Columbia, June 2011
First Received: June 18, 2007 | Last Updated: June 2, 2011 | Phase: Phase 3 | Start Date: December 2010
Overall Status: Terminated | Estimated Enrollment: 50
  • …
  • Tell a FriendPrint

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression...

Brief Summary

Official Title: “An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease”

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

  • Study Type: Interventional
  • Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Study Primary Completion Date: June 2011

Detailed Clinical Trial Description

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Intervention(s) in this Clinical Trial

  • Drug: Escitalopram
    • See Detailed Description.

Outcome Measures for this Clinical Trial

Primary Measures

  • Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.
    • Time Frame: Unspecified
      Safety Issue?: No

Secondary Measures

  • Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study
    • Time Frame: Unspecified
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • > 50 years
  • Male & female
  • Alzheimer's disease
  • Depressive episode

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 50 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: University of British Columbia Other

Overall Clinical Trial Officials and Contacts

Kiran Rabheru, MD Principal Investigator University of British Columbia  

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00488670

Study ID Number: H07-00050

ClinicalTrials.gov Identifier: NCT00488670

Health Authority: Canada: Health Canada

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00488670